What is Amyloidosis?

Amyloidosis is the name given to a group of rare disorders in which amyloid deposits, consisting of misfolded proteins which are relatively insoluble, deposit and accumulate in tissues and organs of the body. As these deposits progressively build up they interfere with the working of the organs. Without treatment this will eventually leads to organ failure.

Over the past 20 years there has been a greater understanding of these complicated diseases.

Although amyloidosis is still considered incurable, earlier diagnosis. improved technology for diagnosing and typing the diseases, new ways of assessing organ damage and the introduction of new treatments has resulted in many patients experiencing remission and leading busy, productive lives.

Much research is being carried around the world to develop new treatments for all types of amyloidosis.

Early diagnosis remains essential for optimum treatment.

The rarity of these conditions, the lack of awareness and the fact that the symptoms mimic other more common diseases results in many patients being diagnosed late, often after seeing a number of doctors.

Read Crystal’s story about her father’s late diagnosis

Amyloidosis can be:

Acquired (not a condition you are born with but develops over time)
or
Hereditary (occurs due to a faulty gene passed down through generations).

Most types of amyloidosis are described as systemic diseases, meaning the amyloid forming protein circulates in the blood and deposits in one or several organs of the body. Why different organs are affected in different individuals is yet to be fully worked out.

However, there is a type of amyloidosis which is referred to as localised because the amyloid protein is produced and deposited only in one area of the body.

How many and what types of amyloidosis are there?

Over 30 different types of amyloidosis have been identified, each caused by a different protein. Many of these are obscure and cause few problems. Each type of amyloidosis is different, requiring different treatment.

Amyloid deposits occur when an amyloid forming protein misfolds to take on a new structure of shape. This new shape allows one misfolded protein to stack upon an other in a “spiral staircase” fashion where each misfolded protein represents a “step” in the staircase. This spiral staircase forms the fibrillar structure called amyloid.

How are the different types of amyloidosis classified?

Amyloidosis is classified according to the main protein that causes that particular type of amyloidosis. The name of each type of amyloid protein consists of “A” for amyloid followed by an abbreviation for the protein that makes up the amyloid deposits. For example, in AL amyloidosis the A stands for amyloid and L for the type of fibril protein, light chain.

Amyloidosis was previously classified as “primary” (occurring on their own) or “secondary” (occurring secondary to another underlying condition), but this terminology was confusing and is no longer used.

The Most Common Types of Amyloidosis are:

AL amyloidosis is formed from misfolded immunoglobulin light chains that are produced by plasma cells in the bone marrow. Usually these plasma cells are benign, but occasionally the amyloid forming light chain protein can be produced by a cancer of plasma cells called Multiple Myeloma. About 15% of patients with Multiple Myeloma will also develop AL amyloidosis. Patients with AL amyloidosis rarely go on to develop myeloma.

AA amyloidosis occurs when the Serum Amyloid A (SAA) protein increases in some people substantially in response to a long-term inflammatory disorder such as rheumatoid arthritis.

Hereditary amyloidosis occurs when a gene mutation is inherited, leading to the life-long production of an abnormal or variant protein. The most common types of hereditary amyloidosis are ATTRv (transthyretin gene mutation) and AFib (fibrinogen-alpha chain gene mutation).

Wild type ATTRwt, previously known as Senile Amyloidosis, occurs when normal or “wild type” transthyretin amyloid deposits in the heart. This is NOT an inherited disease.

Localised Amyloidosis occurs when the the amyloid protein is produced and deposited in one part of the body only.

NB: Alzheimers disease and Cerebral Amyloid Angiopathy (CAA) are not considered to be forms of amyloidosis. These diseases are therefore not treated in the Australian Amyloidosis Centres and not mentioned on this web site.

Click on the different types of amyloidosis for more information.

How common is amyloidosis?

In Australia amyloidosis is not a reportable disease so there is no way of knowing how many people have been diagnosed with any of the types of amyloidosis each year. Overall, a recent study has shown that there are 12 new cases per million population diagnosed each year in Australia. It is likely that amyloidosis is more common than this because of undiagnosed cases, particularly of the ATTRwt type.

What are the symptoms of amyloidosis?

Symptoms will depend on the type of amyloidosis and also which tissues and organs are affected and to what degree. Symptoms often mimic those seen in other more common diseases.

Go to individual types of amyloidosis for information on symptoms relevant to each disease.
Due to the rarity of this group of diseases and vagueness of symptoms, diagnosis may be difficult and delayed.

Dr Morie Gertz from the Mayo Clinic in the USA advocates that if a patient presents to a doctor with the symptoms listed below, amyloidosis should always be considered.

  • Nephrotic range proteinuria
  • Infiltrative cardiomyopathy resulting in heart failure with preserved ejection fraction
  • Peripheral and/or autonomic neuropathy
  • Unexplained hepatomegaly
  • Dysmotility of the bowel with either pseudo obstruction or steatorrhea

How is amyloidosis diagnosed?

  • There is no single blood test that will diagnose amyloidosis.
  • Diagnosis usually begins when a doctor suspects the patient’s symptoms may be due to amyloidosis and starts to run tests or sends the patient to another
  • doctor specializing in the treatment of amyloidosis.
  • A diagnosis is usually made through a tissue or organ biopsy
    • The biopsy is stained with the dye Congo red in the laboratory.
    • If amyloid is present, the biopsy will appear red under normal light and green (apple-green birefringence) under special polarized light.
  • In some circumstances, a DPD bone scan can diagnose heart involvement by ATTR amyloidosis, enabling the diagnosis to be reliably made without the need for a tissue biopsy.
  • Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
  • This procedure is not reliable in patients with a monoclonal gammopathy.

This involves removing a small piece of tissue for microscopic examination from the symptomatic organ thought to be involved by amyloid or from a distant site such as the fat pad on the tummy, the gastrointestinal tract, the lip or the bone marrow.

A bone marrow biopsy may also be performed to establish the presence of abnormal plasma cells when AL is suspected.

Further tests may also be run to:

  • Identify the type of amyloidosis. This is imperative as the treatment for each type is different
  • Establish which organs are affected by the amyloid deposition and to what degree
  • Establish the general health of the patients and any other health problems which may affect treatment.

These test may include:

  • Serum Free light chain Assay
  • A number of other blood tests
  • Urine tests
  • Echocardiogram
  • ECG
  • CT scan, MRI
  • DNA test may also be performed to diagnose or exclude one of the hereditary types of amyloidosis.

It is usually only when all these results have been collated and consideration is given also to:

  • Patients age
  • Where they live
  • Previous treatments
  • Whether a treatment trial is available

that a treatment plan is made by the multidisciplinary team in consultation with the patient and family.

Some of the tests above will be ordered routinely throughout treatment or before visits to the doctor to check:

  • Progress of any treatment
  • Effects of any treatment
  • Status of organ function
  • Status of the disease
  • General health of the patient.

Treatment

Treatment is very different for each type of amyloidosis and is always geared to the needs and health of the individual patient.

Treatment should ideally be recommended after careful review by experienced amyloidosis treatment teams.
(Click here to view the contact details for treatment clinics in Australia.)

Because of the complex nature of these diseases care is usually offered by a multidisciplinary team as below

  • Cardiologists
  • Gastroenterologists
  • Haematologists
  • Immunologists
  • Neurologists
  • Renal physicians
  • Specialized nurses
  • Social workers/Counsellors

A patient may not be looked after by all the specialists listed above. This will depend on the type of amyloidosis they have and which organs are affected.

The members of the team may not always work in the same place. e.g. patients visiting a specialized center may see a number of doctors once or twice a year. If the patients live some distance away they may then be looked after by the local G.P and specialist physician with communication being kept between all treating doctors.

Goals of treatment are similar in all types of amyloidosis:

  • To try and reduce the production of the amyloid forming precursor protein or to interfere with the misfolding process and therefore stop the amyloid depositing into the organs and tissues
  • To support and preserve the affected organs
  • To improve the patient’s quality of life.

A brief overview of treatment options for the different types of amyloidosis.

At this time around the world amyloidosis is still considered incurable.

  • AL Amyloidosis
    • Treatment is directed towards stopping or slowing the production of the abnormal immunoglobulin light chains produced in the bone marrow
    • Chemotherapy drugs, often with steroids, proven in the treatment of myeloma, have traditionally been used in the treatment of AL amyloidosis. Recently new drugs have been introduced and hold great promise.
    • In a highly selected group of patients with AL amyloidosis, a stem cell transplant may be recommended.
  • Hereditary ATTR and Wild type ATTR
    • Chemotherapy has no place in the treatment of ATTR amyloidosis
    • Options available on the PBS to slow the course of these diseases are limited at present but new promising treatments are being trialed overseas and in Australia.
    • In highly selected patients liver transplant has been shown to successfully stop the production of the ATTRv protein.
  • AA amyloidosis
    • The treatment consists of controlling and suppressing the underlying chronic inflammatory disease resulting in the reduction the production of the SAA.
  • Localised Amyloidosis
    • Usually treated with localized surgery or laser surgery.

Treatments used to preserve the viability of the damaged organs and enhance quality of life are extremely important in all types of amyloidosis

Click on the different types of amyloidosis shown in the horizontal bar for more in depth information on each type of amyloidosis.

Amyloidosis Awareness (narrated by Michael York)